Introduction The aim of this study was to evaluate the spectrum of skeletal findings on dual-phase fluorine-18-fluoroethylcholine ( 18 F-FECH) PET/CT performed during the work-up of patients referred for suspected prostate cancer relapse. F-FECH PET/CT in 45 patients, including 31 (43%) in the pelvis, 17 (23%) in the spine (cervical 3, thoracic 8 and lumbar spine 6) and 10 (13%) in the ribs. Evaluation of low-dose CT in combination with PET helped to characterize benign findings in 21 (29%) lesions. The SUV max for all except one benign lesion ranged from 0.49 to 2.15. In 51 (71%) lesions because of metastatic disease, SUV max was 0.6-11.6 for those classified as sclerotic on low-dose CT, 0.7-8.58 for lytic lesions, 1.1-7.65 for isodense lesions and 1.27-3.53 for mixed lytic/sclerotic lesions. Of the 56 18 F-FECH-avid lesions, 21 lesions showed avidity on bone scan [3 (23%) of the 13 isodense lesions, 14 (40%) of the 35 sclerotic lesions, 2 (50%) of the lytic lesions and 2 (50%) of the mixed sclerotic/lytic lesions].
Introduction
Biochemical recurrence after radical prostatectomy or radiation therapy has been reported in 27-53% of patients [1] . Radiology and nuclear medicine techniques play an important role in the detection of local relapse and lymph node and skeletal metastases. Most institutes rely on MRI for this purpose, with increasing emphasis on the multiparametric technique. The main advantage of MRI is its excellent anatomic resolution. Nevertheless, PET/CT offers benefits because of its increasing ability to demonstrate functional characteristics, thereby facilitating differentiation between benign and malignant lesions. PET imaging is based on labelling of small, biologically and clinically significant molecules with positron emitters. A variety of compounds have been used for this purpose, for example, sugar, amino acids, nucleic acids, receptor-binding ligands, water and oxygen. Physiological maps of functions or processes relevant to the labelled molecules can be created in real time by imaging the temporal distribution of these compounds [2] .
In the past decade, tremendous work has been carried out in elucidating the potential role of PET biomarkers in supplementing MRI for the detection of metastatic disease, including in morphologically normal lymph nodes, the bone marrow and the skeleton. Although fluorine-18-fluorodeoxyglucose ( 18 F-FDG) is the most common PET/CT tracer worldwide, the results in respect of prostate cancer detection are not very good [3] . Consequently, other tracers have been investigated for this purpose and choline has emerged as one of the most common non-18 F-FDG PET biomarkers for the evaluation of prostate cancer [4] .
In a meta-analysis [5] , it was found that MRI and choline PET/CT were more accurate than bone single-photon emission computed tomography (SPECT) and bone scintigraphy (BS) for detecting bone metastases in patients with prostate cancer. The sensitivity and specificity of MRI on a per-patient basis were 95 and 96%, respectively, whereas those of choline PET/CT were approximately 87 and 97%, respectively. Although choline PET/CT had the highest specificity on a per-patient basis, MRI was significantly better than choline PET/CT (P < 0.05) and BS (P < 0.05) for the detection of bone metastases from prostate cancer. The area under the curve estimate for MRI (0.9870) on a per-patient basis was also significantly higher than those for choline PET/CT (0.9541, P < 0.05) and BS (0.8876, P < 0.05). On a per-lesion basis, choline PET/CT had a higher area under the curve (0.9494) than bone SPECT (0.9381) and BS (0.7736).
In-vitro data have shown greater 18 F-fluorocholine than 18 F-FDG uptake in androgen-dependent (LNCaP) and androgen-independent (PC-3) prostate cancer cells [6] . A meta-analysis by Shen and colleagues showed that on a per-patient basis, MRI was better than choline PET/CT and bone scan. Choline PET/CT was found to have the highest diagnostic odds ratio compared with bone SPECT and bone scan.
There are three commonly used choline-based tracers, namely, fluorine-18-fluoroethylcholine ( 18 F-FECH), 18 F-methylcholine and 11 C-choline, which have a similar physiological biodistribution [7] . The aim of the current study was to evaluate the spectrum of skeletal findings on 18 F-FECH PET/CT in patients undergoing investigation for biochemical relapse of prostate cancer.
Materials and methods
A total of 300 18 F-FECH PET/CT scans were evaluated prospectively for the detection of skeletal findings in patients with suspected prostate cancer relapse. 18 F-FECH was provided by Erigal (Erigal Limited, Surrey, UK), synthesized as described by Hara et al. [8] . All QC parameters were fulfilled during the commercial preparation. Patients were injected with 300-370 MBq of 18 F-FECH (effective dose 12.95 mSv). Whole-body PET/CT images were acquired 60 min after tracer injection. A 90 min postinjection dedicated view of the pelvis was also obtained. Owing to the rapid excretion of 18 F-FECH in urine, patients were asked to empty their bladder before imaging. The CT acquisition parameters were as follows: scout 120 kVp, 10 mA; CT 140 kVp, 80 mA, 0.8 s, pitch 1.75; and CT slices 5 mm (70-cm FOV PET AC), 2.5 mm (50-cm FOV Std), 2.5 mm (50-cm FOV Lung). PET acquisition parameters were as follows: 3D attenuation-corrected and non-attenuation-corrected images, 20 subsets with iterative reconstructions. CT images were used to produce attenuation correction values for PET emission reconstruction and fused PET/CT presentation. The images were read by a nuclear medicine physician (with 20 years' experience) and a radionuclide radiologist (with 5 years' experience). The low-dose CT features of all cases were categorized into four groups (isodense, sclerotic, lytic and mixed lytic/sclerotic) and maximum standardized uptake values (SUV max ) were calculated. Planar bone scan images were acquired after an intravenous injection of technetium99m-methylene diphosphonate ( 99m Tc-MDP) and correlation was made with 18 F-FECH PET/CT for detection of skeletal lesions.
Benign lesions on PET/CT were those that were situated at sites of previous trauma, joints with arthritic changes (loss of disc space, periarticular sclerosis, subarticular cyst formation, periarticular osteophytes), intervertebral discs with degenerative changes, facial sinuses with features of sinusitis, avascular necrosis, thickened cortex with bone expansion and coarse trabecular pattern (Paget's disease) and ground glass change (fibrous dysplasia). Malignant lesions had 18 F-FECH avidity, intramedullary location and associated altered morphology, that is, sclerotic, lytic or mixed pattern. The identification of these lesions was made on the basis of a subjective assessment.
If the lesion was not metabolically active, but showed CT abnormality, this either reflects a nonviable lesion or apoptosis. Lesions that are found to be suspicious on PET/CT and there is concordance with other imaging modalities are considered highly suspicious for metastatic disease. For the purpose of this study (in the absence of histology), we have relied on the avidity of the lesions on PET component as the gold standard. At the same time, we have highlighted the weakness of the gold standard. This reflects the challenges faced by the radiologists and nuclear medicine physicians in multidisciplinary team settings.
No institutional review board approval was obtained for this study. The patients were evaluated as imaging was performed as part of their standard of care.
Results
The age range of the 300 patients was 50-90 years (mean: 71.3 years) and prostate-specific antigen (PSA) values were 0.04-372 ng/ml (Roche Modular method). A total of 72 lesions were detected on 18 F-FECH PET/CT in 45 (15%) patients.
Anatomically, the distribution of lesions was similar to what is observed in cases of metastatic prostate cancer. In our study of the 72 lesions, 31 were found in the pelvis, 17 in the spine (cervical 3, thoracic 8 and lumbar spine 6), 10 in the ribs, four in the sternum, three in the bone marrow, three in the skull, two in the scapula, one in the clavicle and one in the femur.
The final interpretation of the lesions as benign or malignant on 18 F-FECH PET/CT was based on overall anatomical appearances of the lesions and avidity (Fig. 1a) . Benign findings (21/72) included bone island (13), avascular necrosis (1), fibrous dysplasia (1), Paget's disease (1), vertebral fractures (2), advanced focal degenerative changes (2) and inflammatory changes (maxillary sinus) (1). The SUV max for vast majority of benign lesions ranged from 0.49 to 2.15. Only one case in this case cohort, with fibrous dysplasia, had very high SUV max (10.8) .
The malignant lesions were further subcategorized on the basis of anatomical appearances on the low-dose CT as isodense, sclerotic, lytic and mixed lytic or sclerotic lesions. A total of 51 lesions were considered to be of malignant aetiology. The SUV max values for the malignant lesions ranged from 0.6 to 11.6. The lytic lesions had SUV max in the range of 2.36-8.58, sclerotic lesions 0.6-11.6, isodense lesions 2-7.65 and mixed lytic/sclerotic lesions 2.75-3.53. There were three cases of bone marrow uptake; two were attributed to metastatic disease and one to recent treatment of leukaemia. A flow chart of SUV max range of different skeletal lesions is shown in Fig. 1b . Tc-MDP bone scan was not available were excluded from the analysis. A total of 56/59 lesions were found to be avid on 18 F-choline PET/ CT. The SUV max value 0.6-11.6. Overall, 37.5% (21/56 lesions) showed osteoblastic activity, whereas 62.5% (35/56 lesions) were nonavid on bone scan (Fig. 1c) . The PSA value ranged from 0.04 to 372. Detailed analysis of the lesions as isodense, sclerotic, lytic or mixed, SUV max range, bone scan avidity and PSA values are listed in Table 1 .
There were only three lesions that were nonavid on 18 F-FECH PET/CT, but were avid on the 99m Tc-MDP bone scan. All three of these were sclerotic lesions; SUV max range was 1.06-1.08 and the PSA value was 3.6-240 (Table 2 ). Figure 2 shows the scatter plot of SUV max values in relation to lesion characterization as benign or malignant. We noted minimal overlap of benign and malignant lesions above SUV max of 2.5.
Discussion
To our knowledge, this is the first study to analyse the correlation between lesion-based analysis of skeletal findings on low-dose CT, bone scan and quantification data obtained with 18 F-FECH PET/CT. It was observed that 29% of the 18 F-FECH PET/CT-positive lesions had a benign aetiology. The study also shows the superiority of 18 F-FECH PET/CT over bone scan, given that bone scan detected only 37.5% of the 18 F-FECH-avid lesions.
The skeleton is the second most frequent site (after lymph nodes) for metastases from prostate cancer, and the incidence of skeletal involvement is 65-75% among patients with advanced disease [9] . Among the 15% of patients with bone lesions in this study, 71% of the lesions were because of metastatic disease. The distribution of skeletal lesions overlapped with the sites of spread of prostate cancer and 43% of the lesions were seen in the pelvis (31/72 lesions) and 23.6% in the spine (17/72 lesions), with scattered foci of uptake in the remainder of the skeleton. The anatomical area covered in the bone scan (skull vertex to feet) exceeds that covered on 18 F-FECH PET/CT (skull vertex to mid thigh). Bone scan did not detect any lesion in the lower limbs, which were not covered on 18 F-FECH PET/CT.
A total of 23/51 (45%) malignant lesions were noted to be sclerotic and of these, 20.83% (15) were avid on 
1.06-1.08 3.6-240
CT, computed tomography; 18 F-FECH, fluorine-18-fluoroethylcholine; NA, not available; PSA, prostate-specific antigen; SUV max , maximum standardized uptake value. Maximum standardized uptake values (SUV max ) of benign lesions (B) and malignant lesions (M). There is an overlap of SUV max values between benign and malignant lesions. The only outlier in the benign category with intense uptake was a case of fibrous dysplasia with SUV max greater than 11. BM, bone marrow uptake.
18 F-FECH PET/CT. Isodense but avid lesions fall into the category of 'discordant lesions' and pose a different diagnostic dilemma. Detection of isodense but 'neoplastic lesions' is a real challenge faced while reporting oncology scans. The majority of these lesions have a Hounsfield unit value very similar to that of the adjacent bone matrix and these lesions are easily missed on diagnostic CT scans even when intravenous contrast is administered. Increased avidity of these lesions as detected by 18 F-FECH PET/CT helps to distinguish them from the surrounding bone. Bone metastases undergo osteoblastic healing response with treatment. The isodense lesions may become sclerotic and these lesions can be easily labelled as progressive disease. In this study, there were 13 isodense lesions (SUV max range: 1.1-7.65). Interestingly, of these, only three (23.1%) were avid on bone scan whereas the majority (76.9%) were nonavid. Even on retrospective review of this specific cohort of patients, we could not identify these lesions on the low-dose CT component of the PET/CT. Focal 18 F-FECH in isodense lesions reflects bone marrow infiltration (Fig. 5 ). Caution should be exercised when monitoring isodense lesions. Reduction in choline uptake with sclerosis can distinguish osteoblastic healing response from progressive disease [10] . Figures 3-6 show different examples from this study.
There were three osteoblastic lesions on 99m Tc-MDP bone scan, which were nonavid on 18 F-FECH PET/CT. These included old fractures undergoing osteoblastic healing response. These were situated at the site of sternal fracture (SUV max : 1.7, PSA 3.6), superior end plate fracture at the T12 vertebra (SUV max : 1.06, PSA 9.2) and the right 10 th rib fracture (SUV max : 1.08, SUV max : 240). The patient with rib fracture received close serial followup. This patient was also found to have a fracture of the eighth rib on the same side that was only visible on the low-dose CT component and nonavid on bone scan and 18 F-FECH PET/CT. Because of the symmetrical nature but very high PSA, a differential of fractures and metastatic disease was made. These were found to be stable on three serial bone scans over a period of 2 years and also on two serial CT Scans over 12 months. The patient was placed on hormones, with a gradual decline of PSA from 240 to 29.79, 13.07 and 9.14.
Our cohort showed that quantification of 18 F-FECH uptake cannot characterize skeletal lesions as benign or malignant in patients undergoing investigation for biochemical relapse of prostate cancer and furthermore does not correlate with the isodense, sclerotic, lytic or mixed lytic/sclerotic status of the lesions.
A major limitation of our study is that the bone scan images were planar images and lacked SPECT/CT, which can help with lesion characterization. At our institution, staging investigations for prostate cancer include planar images as the standard of care in the vast majority of prostate cancer patients.
Histopathological correlation was not available in all cases. Our institute is a tertiary referral centre to which heterogeneous groups of patients are referred for imaging from a variety of hospitals. We relied on the low-dose CT features to characterize the patients and correlated findings with available bone scans. This approach is suboptimal, but the study indicates that not all avid lesions on 18 F-FECH PET are because of a metastatic disease process. (a, b) On computed tomography (CT), there is no evidence of sclerosis, lysis, pedicular destruction or prevertebral or paravertebral soft tissue abnormailty to indicate metastatic disease. (b) Axial PET/CT and lowdose CT show an intensely avid lesion at the upper thoracic vertebra, which is in keeping with metastatic disease. In addition, there is an isodense metastatic deposit involving the left fourth rib.
Conclusion

18
F-FECH PET/CT identified bone lesions in 15% of the patients with suspected prostate cancer relapse; 71% of the lesions were because of bone metastases and 29% were because of benign aetiology. 
